Definitions and calculations — MCQs

10 questions

A scientist in Chicago is studying a new blood test to detect Ab to EBV with increased sensitivity and specificity. So far, her best attempt at creating such an exam reached 82% sensitivity and 88% specificity. She is hoping to increase these numbers by at least 2 percent for each value. After several years of work, she believes that she has actually managed to reach a sensitivity and specificity much greater than what she had originally hoped for. She travels to China to begin testing her newest blood test. She finds 2,000 patients who are willing to participate in her study. Of the 2,000 patients, 1,200 of them are known to be infected with EBV. The scientist tests these 1,200 patients' blood and finds that only 120 of them tested negative with her new exam. Of the patients who are known to be EBV-free, only 20 of them tested positive. Given these results, which of the following correlates with the exam's specificity?

Group of 100 medical students took an end of the year exam. The mean score on the exam was 70%, with a standard deviation of 25%. The professor states that a student's score must be within the 95% confidence interval of the mean to pass the exam. Which of the following is the minimum score a student can have to pass the exam?

An infectious disease investigator is evaluating the diagnostic accuracy of a new interferon-gamma-based assay for diagnosing tuberculosis in patients who have previously received a Bacillus Calmette-Guérin (BCG) vaccine. Consenting participants with a history of BCG vaccination received an interferon-gamma assay and were subsequently evaluated for tuberculosis by sputum culture. Results of the study are summarized in the table below. Tuberculosis, confirmed by culture No tuberculosis Total Positive interferon-gamma assay 90 6 96 Negative interferon-gamma assay 10 194 204 Total 100 200 300 Based on these results, what is the sensitivity of the interferon-gamma-based assay for the diagnosis of tuberculosis in this study?

A mother presents to the family physician with her 16-year-old son. She explains, "There's something wrong with him doc. His grades are getting worse, he's cutting class, he's gaining weight, and his eyes are often bloodshot." Upon interviewing the patient apart from his mother, he seems withdrawn and angry at times when probed about his social history. The patient denies abuse and sexual history. What initial test should be sent to rule out the most likely culprit of this patient's behavior?

You conduct a medical research study to determine the screening efficacy of a novel serum marker for colon cancer. The study is divided into 2 subsets. In the first, there are 500 patients with colon cancer, of which 450 are found positive for the novel serum marker. In the second arm, there are 500 patients who do not have colon cancer, and only 10 are found positive for the novel serum marker. What is the overall sensitivity of this novel test?

A 27-year-old man interested in pre-exposure therapy for HIV (PrEP) is being evaluated to qualify for a PrEP study. In order to qualify, patients must be HIV- and hepatitis B- and C-negative. Any other sexually transmitted infections require treatment prior to initiation of PrEP. The medical history is positive for a prior syphilis infection and bipolar affective disorder, for which he takes lithium. On his next visit, the liver and renal enzymes are within normal ranges. HIV and hepatitis B and C tests are negative. Which of the following about the HIV test is true?

A research group wants to assess the safety and toxicity profile of a new drug. A clinical trial is conducted with 20 volunteers to estimate the maximum tolerated dose and monitor the apparent toxicity of the drug. The study design is best described as which of the following phases of a clinical trial?

A medical research study is beginning to evaluate the positive predictive value of a novel blood test for non-Hodgkin’s lymphoma. The diagnostic arm contains 700 patients with NHL, of which 400 tested positive for the novel blood test. In the control arm, 700 age-matched control patients are enrolled and 0 are found positive for the novel test. What is the PPV of this test?

During an evaluation of a new diagnostic imaging modality for detecting salivary gland tumors, 90 patients tested positive out of the 100 patients who tested positive with the gold standard test. A total of 80 individuals tested negative with the new test out of the 100 individuals who tested negative with the gold standard test. What is the positive likelihood ratio for this test?

Q10

You are tasked with analyzing the negative predictive value of an experimental serum marker for ovarian cancer. You choose to enroll 2,000 patients across multiple clinical sites, including both 1,000 patients with ovarian cancer and 1,000 age-matched controls. From the disease and control subgroups, 700 and 100 are found positive for this novel serum marker, respectively. Which of the following represents the NPV for this test?

Definitions and calculations US Medical PG Practice Questions and MCQs

Question 1: A scientist in Chicago is studying a new blood test to detect Ab to EBV with increased sensitivity and specificity. So far, her best attempt at creating such an exam reached 82% sensitivity and 88% specificity. She is hoping to increase these numbers by at least 2 percent for each value. After several years of work, she believes that she has actually managed to reach a sensitivity and specificity much greater than what she had originally hoped for. She travels to China to begin testing her newest blood test. She finds 2,000 patients who are willing to participate in her study. Of the 2,000 patients, 1,200 of them are known to be infected with EBV. The scientist tests these 1,200 patients' blood and finds that only 120 of them tested negative with her new exam. Of the patients who are known to be EBV-free, only 20 of them tested positive. Given these results, which of the following correlates with the exam's specificity?

A. 82%
B. 90%
C. 84%
D. 86%
E. 98% (Correct Answer)

Explanation: ***98%*** - **Specificity** measures the proportion of **true negatives** among all actual negatives. - In this case, 800 patients are known to be EBV-free (actual negatives), and 20 of them tested positive (false positives). This means 800 - 20 = 780 tested negative (true negatives). Specificity = (780 / 800) * 100% = **98%**. *82%* - This value represents the *original sensitivity* before the scientist’s new attempts to improve the test. - It does not reflect the *newly calculated specificity* based on the provided data. *90%* - This value represents the *newly calculated sensitivity* of the test, not the specificity. - Out of 1200 EBV-infected patients, 120 tested negative (false negatives), meaning 1080 tested positive (true positives). Sensitivity = (1080 / 1200) * 100% = 90%. *84%* - This percentage is not directly derived from the information given for either sensitivity or specificity after the new test results. - It does not correspond to any of the calculated values for the new test's performance. *86%* - This percentage is not directly derived from the information given for either sensitivity or specificity after the new test results. - It does not correspond to any of the calculated values for the new test's performance.

Question 2: Group of 100 medical students took an end of the year exam. The mean score on the exam was 70%, with a standard deviation of 25%. The professor states that a student's score must be within the 95% confidence interval of the mean to pass the exam. Which of the following is the minimum score a student can have to pass the exam?

A. 45%
B. 63.75%
C. 67.5%
D. 20%
E. 65% (Correct Answer)

Explanation: ***65%*** - To find the **95% confidence interval (CI) of the mean**, we use the formula: Mean ± (Z-score × Standard Error). For a 95% CI, the Z-score is approximately **1.96**. - The **Standard Error (SE)** is calculated as SD/√n, where n is the sample size (100 students). So, SE = 25%/√100 = 25%/10 = **2.5%**. - The 95% CI is 70% ± (1.96 × 2.5%) = 70% ± 4.9%. The lower bound is 70% - 4.9% = **65.1%**, which rounds to **65%** as the minimum passing score. *45%* - This value is significantly lower than the calculated lower bound of the 95% confidence interval (approximately 65.1%). - It would represent a score far outside the defined passing range. *63.75%* - This value falls below the calculated lower bound of the 95% confidence interval (approximately 65.1%). - While close, this score would not meet the professor's criterion for passing. *67.5%* - This value is within the 95% confidence interval (65.1% to 74.9%) but is **not the minimum score**. - Lower scores within the interval would still qualify as passing. *20%* - This score is extremely low and falls significantly outside the 95% confidence interval for a mean of 70%. - It would indicate performance far below the defined passing threshold.

Question 3: An infectious disease investigator is evaluating the diagnostic accuracy of a new interferon-gamma-based assay for diagnosing tuberculosis in patients who have previously received a Bacillus Calmette-Guérin (BCG) vaccine. Consenting participants with a history of BCG vaccination received an interferon-gamma assay and were subsequently evaluated for tuberculosis by sputum culture. Results of the study are summarized in the table below. Tuberculosis, confirmed by culture No tuberculosis Total Positive interferon-gamma assay 90 6 96 Negative interferon-gamma assay 10 194 204 Total 100 200 300 Based on these results, what is the sensitivity of the interferon-gamma-based assay for the diagnosis of tuberculosis in this study?

A. 90/96
B. 100/300
C. 194/200
D. 90/100 (Correct Answer)
E. 194/204

Explanation: ***90/100*** - **Sensitivity** measures the proportion of **true positive** cases that are correctly identified by the test. - In this study, there are 90 true positive results (positive interferon-gamma assay in patients with confirmed tuberculosis) out of a total of 100 individuals with confirmed tuberculosis (90 + 10). *90/96* - This calculation represents the **positive predictive value** (90 true positives / 96 total positive tests). - It answers the question: "If the test is positive, what is the likelihood that the patient actually has the disease?" *100/300* - This value represents the prevalence of tuberculosis in the study population (100 confirmed cases / 300 total participants). - It does not reflect a measure of the test's diagnostic accuracy. *194/200* - This value represents the **specificity** of the test (194 true negatives / 200 total individuals without tuberculosis). - Specificity measures the proportion of true negative cases that are correctly identified by the test. *194/204* - This calculation represents the **negative predictive value** (194 true negatives / 204 total negative tests). - It answers the question: "If the test is negative, what is the likelihood that the patient does not have the disease?"

Question 4: A mother presents to the family physician with her 16-year-old son. She explains, "There's something wrong with him doc. His grades are getting worse, he's cutting class, he's gaining weight, and his eyes are often bloodshot." Upon interviewing the patient apart from his mother, he seems withdrawn and angry at times when probed about his social history. The patient denies abuse and sexual history. What initial test should be sent to rule out the most likely culprit of this patient's behavior?

A. Complete blood count
B. Sexually transmitted infection (STI) testing
C. Blood culture
D. Urine toxicology screen (Correct Answer)
E. Slit lamp examination

Explanation: ***Urine toxicology screen*** - The patient's presentation with **declining grades**, **cutting class**, **weight gain**, **bloodshot eyes**, and **irritability** are classic signs of **substance abuse** in an adolescent. - A **urine toxicology screen** is the most appropriate initial test to detect common illicit substances, especially given the clear signs pointing towards drug use. *Slit lamp examination* - This test is used to examine the **anterior segment of the eye**, including the conjunctiva, cornea, iris, and lens. - While the patient has **bloodshot eyes**, this specific test would be more relevant for ruling out ocular infections or injuries, not for diagnosing the underlying cause of systemic behavioral changes. *Complete blood count* - A **complete blood count (CBC)** measures different components of the blood, such as red blood cells, white blood cells, and platelets. - A CBC is a general health indicator and while it can detect infections or anemia, it is not specific or sensitive enough to identify the cause of the behavioral changes described. *Sexually transmitted infection (STI) testing* - Although the patient denies sexual history, all adolescents presenting with certain risk factors or symptoms may warrant STI testing in a broader health assessment. - However, in this scenario, the primary cluster of symptoms (poor grades, cutting class, bloodshot eyes, irritability) points more directly to substance abuse than to an STI. *Blood culture* - A **blood culture** is used to detect the presence of bacteria or other microorganisms in the bloodstream, indicating a systemic infection (sepsis). - The patient's symptoms are not indicative of an acute bacterial bloodstream infection, and a blood culture would not be the initial test for the presented behavioral changes.

Question 5: You conduct a medical research study to determine the screening efficacy of a novel serum marker for colon cancer. The study is divided into 2 subsets. In the first, there are 500 patients with colon cancer, of which 450 are found positive for the novel serum marker. In the second arm, there are 500 patients who do not have colon cancer, and only 10 are found positive for the novel serum marker. What is the overall sensitivity of this novel test?

A. 450 / (450 + 10)
B. 490 / (10 + 490)
C. 490 / (50 + 490)
D. 450 / (450 + 50) (Correct Answer)
E. 490 / (450 + 490)

Explanation: ***450 / (450 + 50)*** - **Sensitivity** is defined as the proportion of actual positive cases that are correctly identified by the test. - In this study, there are **500 patients with colon cancer** (actual positives), and **450 of them tested positive** for the marker, while **50 tested negative** (500 - 450 = 50). Therefore, sensitivity = 450 / (450 + 50) = 450/500 = 0.9 or 90%. *450 / (450 + 10)* - This formula represents **Positive Predictive Value (PPV)**, which is the probability that a person with a positive test result actually has the disease. - It incorrectly uses the total number of **test positives** in the denominator (450 true positives + 10 false positives) instead of the total number of diseased individuals, which is needed for sensitivity. *490 / (10 + 490)* - This is actually the correct formula for **specificity**, not sensitivity. - Specificity = TN / (FP + TN) = 490 / (10 + 490) = 490/500 = 0.98 or 98%, which measures the proportion of actual negative cases correctly identified. - The question asks for sensitivity, not specificity. *490 / (50 + 490)* - This formula incorrectly mixes **true negatives (490)** with **false negatives (50)** in an attempt to calculate specificity. - The correct specificity formula should use false positives (10), not false negatives (50), in the denominator: 490 / (10 + 490). *490 / (450 + 490)* - This calculation incorrectly combines **true negatives (490)** and **true positives (450)** in the denominator, which does not correspond to any standard epidemiological measure. - Neither sensitivity nor specificity uses both true positives and true negatives in the denominator.

Question 6: A 27-year-old man interested in pre-exposure therapy for HIV (PrEP) is being evaluated to qualify for a PrEP study. In order to qualify, patients must be HIV- and hepatitis B- and C-negative. Any other sexually transmitted infections require treatment prior to initiation of PrEP. The medical history is positive for a prior syphilis infection and bipolar affective disorder, for which he takes lithium. On his next visit, the liver and renal enzymes are within normal ranges. HIV and hepatitis B and C tests are negative. Which of the following about the HIV test is true?

A. It is a quantitative test used for screening purposes.
B. It is a qualitative test used for screening purposes. (Correct Answer)
C. A secondary reagent is needed to interpret the results.
D. A known antigen binds directly to the patient's serum.
E. An unknown antigen binds to the known serum.

Explanation: ***It is a qualitative test used for screening purposes.*** - **HIV screening tests** (e.g., 4th generation antibody/antigen combination assays) are typically **qualitative**, meaning they detect the presence or absence of HIV markers, not their exact amount. - These tests are primarily used for broad **screening** of populations to identify potential cases of HIV infection. *It is a quantitative test used for screening purposes.* - **Quantitative tests** for HIV, such as viral load tests, measure the amount of virus in the blood and are typically used for monitoring disease progression or treatment effectiveness, not for initial screening. - Screening tests are designed for high sensitivity to detect infection, even with low viral loads or early antibody responses, making a quantitative measurement less relevant for initial screening. *A secondary reagent is needed to interpret the results.* - While some complex immunoassays might involve multiple steps, modern **HIV screening tests** often use advanced technologies that directly yield results, making a separate secondary reagent for interpretation generally unnecessary. - The results are typically indicated by a color change or a signal detected by an instrument, without requiring an additional interpretive reagent. *A known antigen binds directly to the patient's serum.* - **HIV antibody tests** detect **antibodies** produced by the patient's immune system in response to HIV infection. - In such tests, **known HIV antigens** (from the test kit) bind to **HIV-specific antibodies present in the patient's serum**, not to serum components directly. - This option is incorrect because it omits the critical role of antibodies as the target molecules being detected. *An unknown antigen binds to the known serum.* - This statement describes a different type of immunological assay where an unknown antigen is being identified using a known antibody, which is contrary to how **HIV screening tests** for infection are typically structured. - **HIV screening tests** use known components (e.g., HIV antigens or antibodies) in the test kit to detect unknown components (e.g., HIV antibodies or viral antigens) in the patient's sample.

Question 7: A research group wants to assess the safety and toxicity profile of a new drug. A clinical trial is conducted with 20 volunteers to estimate the maximum tolerated dose and monitor the apparent toxicity of the drug. The study design is best described as which of the following phases of a clinical trial?

A. Phase 0
B. Phase III
C. Phase V
D. Phase II
E. Phase I (Correct Answer)

Explanation: ***Phase I*** - **Phase I clinical trials** involve a small group of healthy volunteers (typically 20-100) to primarily assess **drug safety**, determine a safe dosage range, and identify side effects. - The main goal is to establish the **maximum tolerated dose (MTD)** and evaluate the drug's pharmacokinetic and pharmacodynamic profiles. *Phase 0* - **Phase 0 trials** are exploratory studies conducted in a very small number of subjects (10-15) to gather preliminary data on a drug's **pharmacodynamics and pharmacokinetics** in humans. - They involve microdoses, not intended to have therapeutic effects, and thus cannot determine toxicity or MTD. *Phase III* - **Phase III trials** are large-scale studies involving hundreds to thousands of patients to confirm the drug's **efficacy**, monitor side effects, compare it to standard treatments, and collect information that will allow the drug to be used safely. - These trials are conducted after safety and initial efficacy have been established in earlier phases. *Phase V* - "Phase V" is not a standard, recognized phase in the traditional clinical trial classification (Phase 0, I, II, III, IV). - This term might be used in some non-standard research contexts or for post-marketing studies that go beyond Phase IV surveillance, but it is not a formal phase for initial drug development. *Phase II* - **Phase II trials** involve several hundred patients with the condition the drug is intended to treat, focusing on **drug efficacy** and further evaluating safety. - While safety is still monitored, the primary objective shifts to determining if the drug works for its intended purpose and at what dose.

Question 8: A medical research study is beginning to evaluate the positive predictive value of a novel blood test for non-Hodgkin’s lymphoma. The diagnostic arm contains 700 patients with NHL, of which 400 tested positive for the novel blood test. In the control arm, 700 age-matched control patients are enrolled and 0 are found positive for the novel test. What is the PPV of this test?

A. 400 / (400 + 0) (Correct Answer)
B. 700 / (700 + 300)
C. 400 / (400 + 300)
D. 700 / (700 + 0)
E. 700 / (400 + 400)

Explanation: ***400 / (400 + 0) = 1.0 or 100%*** - The **positive predictive value (PPV)** is calculated as **True Positives / (True Positives + False Positives)**. - In this scenario, **True Positives (TP)** are the 400 patients with NHL who tested positive, and **False Positives (FP)** are 0, as no control patients tested positive. - This gives a PPV of 400/400 = **1.0 or 100%**, indicating that all patients who tested positive actually had the disease. *700 / (700 + 300)* - This calculation does not align with the formula for PPV based on the given data. - The denominator `(700+300)` suggests an incorrect combination of various patient groups. *400 / (400 + 300)* - The denominator `(400+300)` incorrectly includes 300, which is the number of **False Negatives** (patients with NHL who tested negative), not False Positives. - PPV focuses on the proportion of true positives among all positive tests, not all diseased individuals. *700 / (700 + 0)* - This calculation incorrectly uses the total number of patients with NHL (700) as the numerator, rather than the number of positive test results in that group. - The numerator should be the **True Positives** (400), not the total number of diseased individuals. *700 / (400 + 400)* - This calculation uses incorrect values for both the numerator and denominator, not corresponding to the PPV formula. - The numerator 700 represents the total number of patients with the disease, not those who tested positive, and the denominator incorrectly sums up values that don't represent the proper PPV calculation.

Question 9: During an evaluation of a new diagnostic imaging modality for detecting salivary gland tumors, 90 patients tested positive out of the 100 patients who tested positive with the gold standard test. A total of 80 individuals tested negative with the new test out of the 100 individuals who tested negative with the gold standard test. What is the positive likelihood ratio for this test?

A. 80/90
B. 90/100
C. 90/20 (Correct Answer)
D. 90/110
E. 10/80

Explanation: ***90/20*** - The **positive likelihood ratio (LR+)** is calculated as **sensitivity / (1 - specificity)**. To calculate this, we first need to determine the values for true positives (TP), false positives (FP), true negatives (TN), and false negatives (FN). - Given that 90 out of 100 actual positive patients tested positive, **TP = 90** and **FN = 100 - 90 = 10**. Also, 80 out of 100 actual negative patients tested negative, so **TN = 80** and **FP = 100 - 80 = 20**. - **Sensitivity** is the true positive rate (TP / (TP + FN)) = 90 / (90 + 10) = 90 / 100. - **Specificity** is the true negative rate (TN / (TN + FP)) = 80 / (80 + 20) = 80 / 100. - Therefore, LR+ = (90/100) / (1 - 80/100) = (90/100) / (20/100) = **90/20**. *80/90* - This option incorrectly represents the components for the likelihood ratio. It seems to misinterpret the **true negative** count and the **true positive** count. - It does not follow the formula for LR+ which is **sensitivity / (1 - specificity)**. *90/100* - This value represents the **sensitivity** of the test, which is the proportion of true positives among all actual positives. - It does not incorporate the **false positive rate** (1 - specificity) in the denominator required for the positive likelihood ratio. *90/110* - This option incorrectly combines different values, possibly by confusing the denominator for sensitivity or specificity calculations. - It does not correspond to the formula for the **positive likelihood ratio**. *10/80* - This value seems to relate to the inverse of the **false negative rate** (10/100) or misrepresents the relationship between false negatives and true negatives. - It is not correctly structured to represent the **positive likelihood ratio (LR+)**.

Question 10: You are tasked with analyzing the negative predictive value of an experimental serum marker for ovarian cancer. You choose to enroll 2,000 patients across multiple clinical sites, including both 1,000 patients with ovarian cancer and 1,000 age-matched controls. From the disease and control subgroups, 700 and 100 are found positive for this novel serum marker, respectively. Which of the following represents the NPV for this test?

A. 700 / (700 + 300)
B. 700 / (300 + 900)
C. 700 / (700 + 100)
D. 900 / (900 + 100)
E. 900 / (900 + 300) (Correct Answer)

Explanation: ***900 / (900 + 300)*** - The **Negative Predictive Value (NPV)** is the probability that a person with a **negative test result** does not have the disease. It is calculated as **true negatives (TN)** divided by the sum of true negatives and **false negatives (FN)**, i.e., TN / (TN + FN). - In this scenario: there are 1,000 ovarian cancer patients, and 700 tested positive, meaning **300 tested negative (false negatives)**. There are 1,000 controls, and 100 tested positive, meaning **900 tested negative (true negatives)**. Therefore, NPV = 900 / (900 + 300). *700 / (700 + 300)* - This calculation represents the sensitivity of the test, which is the proportion of true positives among all individuals with the disease (700 true positives / 1000 diseased individuals). - It does not account for the true negatives or false positives, which are crucial for determining predictive values. *700 / (300 + 900)* - This formula mixes elements and does not correspond to a standard measure of test validity. - The numerator (700) is the number of true positives, and the denominator incorrectly combines false negatives (300) and true negatives (900). *700 / (700 + 100)* - This calculation represents the **Positive Predictive Value (PPV)**, which is the probability that a person with a **positive test result** actually has the disease (700 true positives / (700 true positives + 100 false positives)). - It does not assess the negative predictive power of the test. *900 / (900 + 100)* - This calculation represents the **specificity** of the test, which is the proportion of true negatives among all individuals without the disease (900 true negatives / 1000 controls). - While this involves true negatives, it does not account for false negatives, which are essential for calculating NPV.

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free